Heterologous HIV-2 challenge of rhesus monkeys immunized with recombinant vaccinia viruses and purified recombinant HIV-2 proteins.
In an attempt to analyse the role of anti-envelope immunity in the protection of rhesus monkeys against an HIV-2 intravenous challenge, rhesus macaques were immunized twice with recombinant HIV-2 ROD vaccinia viruses (10(8) p.f.u. each) at days 0 and 30, followed by booster injections of purified HIV-2 proteins at months 8, 9, 15 and 27. One group of five macaques was immunized with the Gag, Pol, Vif and Nef antigens, whereas a second group received the same antigens with the addition of HIV-2 Env protein. Eight months after the last boost, the animals were challenged by intravenous injection of 100 AID50 of a monkey PBMC-grown stock of HIV-2 SBL. None of the animals was protected in spite of high humoral immune responses on day of challenge as determined by ELISA and Western Blot assays.
Vogt
G
G
Laboratoire de Neuropathologie expérimentale et Neurovirologie, CRSSA, DSV, DPTE, CEA, Fontenay Aux Roses, France.
le Grand
R
R
Vaslin
B
B
Boussin
F
F
Auboyer
M H
MH
Rivière
Y
Y
Putkonen
P
P
Sonigo
P
P
Kieny
M P
MP
Girard
M
M
D016915:AIDS Vaccines / Q000276:immunology / Q000494:pharmacology*; D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D001483:Base Sequence; D015686:Gene Products, env / Q000276:immunology; D015488:HIV Antigens / Q000276:immunology*; D015498:HIV-2 / Q000235:genetics / Q000276:immunology*; D008253:Macaca mulatta; D008969:Molecular Sequence Data; D014614:Vaccines, Synthetic / Q000494:pharmacology; D014616:Vaccinia virus / Q000276:immunology*; D014765:Viral Vaccines / Q000276:immunology / Q000494:pharmacology*
D016915:AIDS Vaccines; D000914:Antibodies, Viral; D015686:Gene Products, env; D015488:HIV Antigens; D014614:Vaccines, Synthetic; D014765:Viral Vaccines